Darleukin clinical trials
Also written L19IL2 and L19-IL2.
How each study uses darleukin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the darleukin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 3
Philogen S.p.A. (9) · Maastricht Radiation Oncology (2) · Maastricht University Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses darleukin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)RecruitingPhase 2Philogen S.p.A.NCT07227350Written as L19IL2
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsRecruitingPhase 2Philogen S.p.A.NCT06284590Written as L19IL2
- A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid TumorsNot yet recruitingPhase 1Philogen S.p.A.NCT07566897Written as L19IL2
- Intratumoral Administration of Daromun in Non-melanoma Skin Cancer PatientsRecruitingPhase 2Philogen S.p.A.NCT04362722Written as L19IL2 +L19TNF
- IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II StudyTerminatedPhase 2Maastricht University Medical CenterNCT03705403Written as Darleukin
- Neoadjuvant L19IL2/L19TNF- Pivotal StudyActive, not recruitingPhase 3Philogen S.p.A.NCT02938299Written as L19IL2 + L19TNF
- Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer PatientsTerminatedPhase 1Philogen S.p.A.NCT01198522Written as L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine
- Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid TumorCompletedPhase 1Maastricht Radiation OncologyNCT02086721Written as L19-IL2
- Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)WithdrawnPhase 2Maastricht Radiation OncologyNCT02735850Written as L19-IL2
- Intratumoral Administration of L19IL2/L19TNFCompletedPhase 2Philogen S.p.A.NCT02076633Written as L19IL2+L19TNF
- A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid TumoursCompletedPhase 1/2Philogen S.p.A.NCT01058538Written as L19IL2
- Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic MelanomaTerminatedPhase 2Philogen S.p.A.NCT01055522Written as Arm 1: L19IL2 + Dacarbazine
Given beside what is tested · 1 — darleukin is usual care or a partner of the new treatment
Codes
What other systems call darleukin · ClinicalTrials.gg INT014506
- UNII (FDA) 2OQ3OPV2F8DARLEUKINOne source FDA
- NCI Thesaurus C90546DarleukinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2OQ3OPV2F8 | DARLEUKIN | One source FDA |
| NCI Thesaurus | C90546 | Darleukin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.